NCT02956473View on ClinicalTrials.gov

Supine MRI in Breast Cancer Patients Undergoing Upfront Surgery or Receiving Neoadjuvant Therapy

NACompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

November 15, 2016

Primary Completion Date

August 31, 2022

Study Completion Date

August 31, 2022

Conditions
Breast Cancer
Interventions
DEVICE

Supine MRI

OTHER

Neoadjuvant Therapy (NAT)

DEVICE

Ultrasound

DEVICE

Mammography

PROCEDURE

Standard of Care

DEVICE

Standard MRI

Trial Locations (2)

02115

Brigham and Women's Hospital, Boston

Dana Farber Cancer Institute, Boston

All Listed Sponsors
lead

Dana-Farber Cancer Institute

OTHER

NCT02956473 - Supine MRI in Breast Cancer Patients Undergoing Upfront Surgery or Receiving Neoadjuvant Therapy | Biotech Hunter | Biotech Hunter